{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T19:31:17Z","timestamp":1781897477879,"version":"3.54.5"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ejps.2021.105954","type":"journal-article","created":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T17:31:38Z","timestamp":1626629498000},"page":"105954","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Development of a novel formulation method to prepare liposomal Epacadostat"],"prefix":"10.1016","volume":"165","author":[{"given":"Sahar","family":"Tahaghoghi-Hajghorbani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahimeh","family":"Khoshkhabar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Rafiei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abolghasem","family":"Ajami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin Reza","family":"Nikpoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Reza","family":"Jaafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Badiee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2021.105954_bib0001","first-page":"129","article-title":"Tryptophan catabolism and cancer immunotherapy targeting IDO mediated immune suppression","volume":"1036","author":"Amobi","year":"2017","journal-title":"Tumor Immune Microenviron. Cancer Progr. Cancer Ther."},{"issue":"2","key":"10.1016\/j.ejps.2021.105954_bib0002","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae\u2014the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2021.105954_bib0003","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0021-9258(18)70226-3","article-title":"Phosphorus assay in column chromatography","volume":"234","author":"Bartlett","year":"1959","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.ejps.2021.105954_bib0004","first-page":"375","article-title":"Cancer immunotherapy: a promising dawn in cancer research","volume":"10","author":"Bondhopadhyay","year":"2020","journal-title":"Am. J. Blood Res."},{"issue":"5","key":"10.1016\/j.ejps.2021.105954_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126159","article-title":"An autocrine cytokine\/JAK\/STAT-signaling induces kynurenine synthesis in multidrug resistant human cancer cells","volume":"10","author":"Campia","year":"2015","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.ejps.2021.105954_bib0006","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.exer.2007.07.014","article-title":"Uveal melanoma expression of indoleamine 2, 3-deoxygenase: establishment of an immune privileged environment by tryptophan depletion","volume":"85","author":"Chen","year":"2007","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejps.2021.105954_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119446","article-title":"Co-delivery of doxorubicin and epacadostat via heparin coated pH-sensitive liposomes to suppress the lung metastasis of melanoma","volume":"584","author":"Chen","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"21","key":"10.1016\/j.ejps.2021.105954_bib0008","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1021\/cr400532z","article-title":"Functional nanomaterials for phototherapies of cancer","volume":"114","author":"Cheng","year":"2014","journal-title":"Chem. Rev."},{"issue":"1","key":"10.1016\/j.ejps.2021.105954_bib0009","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1158\/1541-7786.MCR-18-0362","article-title":"A role for tryptophan-2, 3-dioxygenase in CD8 T-cell suppression and evidence of tryptophan catabolism in breast cancer patient plasma","volume":"17","author":"Greene","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ejps.2021.105954_bib0010","doi-asserted-by":"crossref","unstructured":"G\u00fcnther, J., D\u00e4britz, J. and Wirthgen, E.J.F.i.i. (2019). \"Limitations and off-target effects of tryptophan-related IDO inhibitors in cancer treatment.\" 10: 1801.","DOI":"10.3389\/fimmu.2019.01801"},{"issue":"3","key":"10.1016\/j.ejps.2021.105954_bib0011","first-page":"949","article-title":"The enhanced antitumour response of pimozide combined with the IDO inhibitor L\u2011MT in melanoma","volume":"53","author":"Jia","year":"2018","journal-title":"Int. J. Oncol."},{"issue":"3","key":"10.1016\/j.ejps.2021.105954_bib0012","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ygyno.2017.07.005","article-title":"A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)\u2013only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer","volume":"146","author":"Kristeleit","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejps.2021.105954_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.matdes.2021.109465","article-title":"Immunogenic cell death-inducing chemotherapeutic nanoformulations potentiate combination chemoimmunotherapy","volume":"202","author":"Liu","year":"2021","journal-title":"Mater. Des."},{"issue":"1","key":"10.1016\/j.ejps.2021.105954_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0644-y","article-title":"Targeting the IDO1 pathway in cancer: from bench to bedside","volume":"11","author":"Liu","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.ejps.2021.105954_bib0015","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1166\/jnn.2008.274","article-title":"New aspects of nanopharmaceutical delivery systems","volume":"8","author":"Marcato","year":"2008","journal-title":"J. Nanosci. Nanotechnol."},{"issue":"1","key":"10.1016\/j.ejps.2021.105954_bib0016","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2174\/138920012798356934","article-title":"PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery","volume":"13","author":"Milla","year":"2012","journal-title":"Curr. Drug Metab."},{"issue":"12","key":"10.1016\/j.ejps.2021.105954_bib0017","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1002\/jbm.a.34642","article-title":"Nanoparticle systems as tools to improve drug delivery and therapeutic efficacy","volume":"101","author":"Mishra","year":"2013","journal-title":"J. Biomed. Mater. Res. Part A"},{"key":"10.1016\/j.ejps.2021.105954_bib0018","doi-asserted-by":"crossref","unstructured":"Munn, D.H. and Mellor, A.L.J.T.i.i. (2016). \"IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance.\" 37(3): 193-207.","DOI":"10.1016\/j.it.2016.01.002"},{"key":"10.1016\/j.ejps.2021.105954_bib0019","series-title":"Abstract CT177","author":"Naing","year":"2018"},{"issue":"1","key":"10.1016\/j.ejps.2021.105954_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0351-9","article-title":"Phase Ia study of the indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors","volume":"6","author":"Nayak-Kapoor","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.ejps.2021.105954_bib0021","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ijpharm.2015.08.048","article-title":"Nanoliposome-mediated targeting of antibodies to tumors: IVIG antibodies as a model","volume":"495","author":"Nikpoor","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.ejps.2021.105954_bib0022","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002092","article-title":"Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus","volume":"25","author":"Rebecca","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.ejps.2021.105954_bib0023","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1080\/21691401.2017.1282496","article-title":"Recent advances on liposomal nanoparticles: synthesis, characterization and biomedical applications","volume":"45","author":"Panahi","year":"2017","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.ejps.2021.105954_bib0024","doi-asserted-by":"crossref","unstructured":"Prendergast, G.C. and Jaffee, E.M.J.C.R. (2007). \"Cancer immunologists and cancer biologists: why we didn't talk then but need to now.\" 67(8): 3500-3504.","DOI":"10.1158\/0008-5472.CAN-06-4626"},{"key":"10.1016\/j.ejps.2021.105954_bib0025","doi-asserted-by":"crossref","unstructured":"Prendergast, G.C., Malachowski, W.P., DuHadaway, J.B. and Muller, A.J.J.C.r. (2017). \"Discovery of IDO1 inhibitors: from bench to bedside.\" 77(24): 6795-6811.","DOI":"10.1158\/0008-5472.CAN-17-2285"},{"issue":"3","key":"10.1016\/j.ejps.2021.105954_bib0026","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1021\/la0110085","article-title":"Determination of critical micelle concentration of lipopolymers and other amphiphiles: comparison of sound velocity and fluorescent measurements","volume":"18","author":"Priev","year":"2002","journal-title":"Langmuir"},{"key":"10.1016\/j.ejps.2021.105954_bib0027","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1007\/s10637-020-00950-1","article-title":"A phase 1 study of PF-06840003, an oral indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma","volume":"38","author":"Reardon","year":"2020","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ejps.2021.105954_bib0028","doi-asserted-by":"crossref","unstructured":"Rose, S.J.C.D. (2017). \"Epacadostat shows value in two SCCHN trials.\" 7: 2OF.","DOI":"10.1158\/2159-8290.CD-NB2017-100"},{"issue":"3","key":"10.1016\/j.ejps.2021.105954_bib0029","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1007\/s11095-014-1512-2","article-title":"Liposome encapsulated albumin-paclitaxel nanoparticle for enhanced anti-tumor efficacy","volume":"32","author":"Ruttala","year":"2015","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.ejps.2021.105954_bib0030","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ctrv.2013.11.005","article-title":"Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies","volume":"40","author":"Sideras","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ejps.2021.105954_bib0031","series-title":"Abstract CT116","author":"Siu","year":"2017"},{"issue":"16","key":"10.1016\/j.ejps.2021.105954_bib0032","doi-asserted-by":"crossref","first-page":"22928","DOI":"10.18632\/oncotarget.8216","article-title":"A phase I study of indoximod in patients with advanced malignancies","volume":"7","author":"Soliman","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ejps.2021.105954_bib0033","first-page":"3","volume":"2","author":"Spranger","year":"2014","journal-title":"Mechanism of tumor rejection with doublets of CTLA-4, PD-1\/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment"},{"issue":"2","key":"10.1016\/j.ejps.2021.105954_bib0034","first-page":"129","article-title":"Role of nanoparticle-mediated immunogenic cell death in cancer immunotherapy","volume":"16","author":"Sun","year":"2021","journal-title":"Asian J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ejps.2021.105954_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar2205","article-title":"Inhibition of indoleamine 2, 3-dioxygenase-mediated tryptophan catabolism accelerates collagen-induced arthritis in mice","volume":"9","author":"Sz\u00e1nt\u00f3","year":"2007","journal-title":"Arthritis Res. Ther."},{"issue":"6","key":"10.1016\/j.ejps.2021.105954_bib0036","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2174\/1871520616666161206145521","article-title":"Improved immunogenicity against a Her2\/neu-derived peptide by employment of a Pan HLA DR-binding epitope and CpG in a BALB\/c mice model","volume":"17","author":"Tahaghoghi-Hajghorbani","year":"2017","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"10.1016\/j.ejps.2021.105954_bib0037","doi-asserted-by":"crossref","unstructured":"Vakili-Ghartavol, R., Rezayat, S.M., Faridi-Majidi, R., Sadri, K. and Jaafari, M.R.J.S.r. (2020). \"Optimization of docetaxel loading conditions in liposomes: proposing potential products for metastatic breast carcinoma chemotherapy.\" 10(1): 1-14.","DOI":"10.1038\/s41598-020-62501-1"},{"issue":"4","key":"10.1016\/j.ejps.2021.105954_bib0038","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/1061186X.2017.1367006","article-title":"General overview of lipid\u2013polymer hybrid nanoparticles, dendrimers, micelles, liposomes, spongosomes and cubosomes","volume":"26","author":"Wakaskar","year":"2018","journal-title":"J. Drug Target."},{"issue":"48","key":"10.1016\/j.ejps.2021.105954_bib0039","doi-asserted-by":"crossref","first-page":"84559","DOI":"10.18632\/oncotarget.19187","article-title":"Novel strategies to prevent the development of multidrug resistance (MDR) in cancer","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ejps.2021.105954_bib0040","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jconrel.2011.11.031","article-title":"Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers","volume":"159","author":"Wolinsky","year":"2012","journal-title":"J. Control. Release"},{"issue":"10","key":"10.1016\/j.ejps.2021.105954_bib0041","doi-asserted-by":"crossref","first-page":"5953","DOI":"10.4049\/jimmunol.1001628","article-title":"IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis","volume":"185","author":"Yan","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejps.2021.105954_bib0042","doi-asserted-by":"crossref","unstructured":"Yingchoncharoen, P., Kalinowski, D.S. and Richardson, D.R.J.P.r. (2016). \"Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come.\" 68(3): 701-787.","DOI":"10.1124\/pr.115.012070"},{"issue":"7","key":"10.1016\/j.ejps.2021.105954_bib0043","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.4049\/jimmunol.1201449","article-title":"Myeloid-derived suppressor cells suppress anti-tumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer","volume":"190","author":"Yu","year":"2013","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.ejps.2021.105954_bib0044","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/cmi.2017.143","article-title":"IDO1 in cancer: a Gemini of immune checkpoints","volume":"15","author":"Zhai","year":"2018","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.ejps.2021.105954_bib0045","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jconrel.2013.02.026","article-title":"A simple way to enhance Doxil\u00ae therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer","volume":"168","author":"Zhao","year":"2013","journal-title":"J. Control. Release"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721002578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721002578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:00:14Z","timestamp":1760529614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098721002578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":45,"alternative-id":["S0928098721002578"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105954","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a novel formulation method to prepare liposomal Epacadostat","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105954","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105954"}}